These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 10690508)

  • 1. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
    Kim K; Fisher MJ; Xu SQ; el-Deiry WS
    Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.
    Meng RD; McDonald ER; Sheikh MS; Fornace AJ; El-Deiry WS
    Mol Ther; 2000 Feb; 1(2):130-44. PubMed ID: 10933923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha.
    Sheikh MS; Burns TF; Huang Y; Wu GS; Amundson S; Brooks KS; Fornace AJ; el-Deiry WS
    Cancer Res; 1998 Apr; 58(8):1593-8. PubMed ID: 9563466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
    Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
    Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract.
    Sheikh MS; Huang Y; Fernandez-Salas EA; El-Deiry WS; Friess H; Amundson S; Yin J; Meltzer SJ; Holbrook NJ; Fornace AJ
    Oncogene; 1999 Jul; 18(28):4153-9. PubMed ID: 10435597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of TRAIL (Apo2L), DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2) and TRID (TRAIL receptor 3) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 (HL60/Tax) or MRP (HL60/AR).
    Kim CH; Gupta S
    Int J Oncol; 2000 Jun; 16(6):1137-9. PubMed ID: 10811986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
    Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.
    Eggert A; Grotzer MA; Zuzak TJ; Wiewrodt BR; Ho R; Ikegaki N; Brodeur GM
    Cancer Res; 2001 Feb; 61(4):1314-9. PubMed ID: 11245427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
    Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
    Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
    Kim JH; Ajaz M; Lokshin A; Lee YJ
    Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells.
    Hao C; Beguinot F; Condorelli G; Trencia A; Van Meir EG; Yong VW; Parney IF; Roa WH; Petruk KC
    Cancer Res; 2001 Feb; 61(3):1162-70. PubMed ID: 11221847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antagonist decoy receptor and a death domain-containing receptor for TRAIL.
    Pan G; Ni J; Wei YF; Yu G; Gentz R; Dixit VM
    Science; 1997 Aug; 277(5327):815-8. PubMed ID: 9242610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of apoptosis signaling by Apo2 ligand.
    Marsters SA; Pitti RA; Sheridan JP; Ashkenazi A
    Recent Prog Horm Res; 1999; 54():225-34. PubMed ID: 10548878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
    Pollack IF; Erff M; Ashkenazi A
    Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
    Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
    Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1.
    Bernard D; Quatannens B; Vandenbunder B; Abbadie C
    J Biol Chem; 2001 Jul; 276(29):27322-8. PubMed ID: 11350953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I; Marciniak RA
    Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.